Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
HIV Eradication: One Step Closer
Life Expectancy With HIV Increases Dramatically
Mouth Full of Problems: A Crisis in HIV Dental Care
New Technology Finds Meds That Might Flush Out Hidden HIV Reservoirs
New Hope for HIV Eradication
Personalized Therapeutic Vaccine Shows Promise
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

November 10, 2009

Topical Treatment Works Well for Anal Lesions

Trichloroacetic acid (TCA), a topical liquid sometimes used to treat genital warts, may also be useful as a therapy for anal intraepithelial neoplasia (AIN) in HIV-positive and HIV-negative people, according to a study published in the December issue of the Journal of Acquired Immune Deficiency Syndromes.

Anal lesions from human papillomavirus (HPV) infection are a precursor to anal cancer. They are remarkably common in men who have sex with men (MSM), especially HIV-positive MSM. This is of particular concern, as anal cancer rates among HIV-positive people are on the rise.

Unfortunately, few options are available to treat pre-cancerous anal lesions. The most common method is cauterization—using electrical pulses to burn lesions away—or surgery, which can cause discomfort and complications.

To determine whether TCA, considered to be less invasive than cauterization or surgery, would work well on anal lesions, Jasmeet Chadha Singh, MD, from the St. Luke’s Roosevelt Hospital Center in New York City and her colleagues conducted a study involving 35 HIV-positive and 19 HIV-negative MSM.

Most of the men had moderate-to-severe lesions (AIN grade 2 or 3), as opposed to mild lesions (AIN grade 1) or anal warts exclusively.

An 85 percent concentration of TCA was applied to the lesions with a cotton swab. Researchers treated participants’ lesions with TCA four times, with intervals of about one to two months between treatments. TCA therapy was considered a success if it cleared all of the AIN lesions by the fourth treatment.

Singh’s group found that TCA was successful in 32 percent of those with AIN 2 or 3 lesions. In 29 percent, AIN 2 or 3 lesions were reduced in severity to AIN 1.

TCA was somewhat less effective in HIV-positive MSM, with 34 percent completely clearing the lesions, compared with 47 percent of HIV-negative MSM. Men 48 years old and younger were also more likely than men 49 and older to completely clear the lesions.

Unfortunately, recurrence of the lesions—which is common regardless of the treatment used—occurred in up to 75 percent of those who’d had complete resolution of their lesions within six months of finishing treatment.

TCA was safe and well tolerated, with only 5 percent of the participants complaining of mild discomfort or a flare of psoriasis.

The authors point out one major shortcoming of the study—that TCA was not compared head-to-head with other treatments commonly used to manage AIN, and they recommend that such clinical trials be conducted. They also acknowledge that treatment of anal lesions has not been clearly proved to reduce the rates of anal cancer in the same way that treatment of cervical lesions prevents cervical cancer but that many providers recommend it nevertheless.

Search: Anal intraepithelial neoplasia, AIN, anal lesions, trichloroacetic acid, MSM, Jasmeet Chadha Singh


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

Luis Portal, San Salvador, 2009-11-11 12:37:34
The United Nations Development Fund will be funding studies on AIDS in El Salvador.Do you know about a partner to work with in Central America.

comments 1 - 1 (of 1 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy